Literature DB >> 8405187

The presence of serotonin (5-HT1) receptors negatively coupled to adenylate cyclase in rabbit and human iris-ciliary processes.

N L Barnett1, N N Osborne.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) reduces forskolin-induced stimulation of cyclic AMP in rabbit iris-ciliary body (ICB) homogenates. The effect is dose dependent and can be mimicked by a number of 5-HT1 receptor agonists including 5-carboxamidotryptamine (5-CT) and RU 24969 [5-methoxy-3-(1,2,3,6, tetrahydro-4-pyridinyl)-1-indole]. The inhibitory effects of 5-CT and the 5-HT1A selective agent 8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) on forskolin stimulated adenylate cyclase activity are greater in isolated ciliary processes than in the iris musculature. Spiperone and propranolol significantly antagonize the action of 5-CT in the iris-ciliary body, while ketanserin (5-HT2 antagonist) and ICS 205930 (5-HT3/4 blocker) were without influence, indicating the presence of the 5-HT1A subtype of receptor. Studies carried out on human ICB homogenates also suggest the presence of 5-HT1A-like receptors, although these receptors are not identical to those in rabbit. Similarities include dose-dependent decreases in cAMP levels stimulated by forskolin elicited by 1-(3-chlorophenyl) piperazine (mCPP), 5-CT and 8-OH-DPAT. Moreover, the inhibitory effect of 5-CT can also be significantly reduced by the 5-HT1 receptor antagonist, propranolol. However, unlike the case of rabbit tissue, spiperone was ineffective in abolishing the 5-CT response in human ICB homogenates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405187     DOI: 10.1006/exer.1993.1116

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

1.  Bilateral symptomatic angle closure associated with a regular dose of citalopram, an SSRI antidepressant.

Authors:  P Massaoutis; D Goh; P J Foster
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

2.  Expression of serotonin receptor mRNAs in human ciliary body: a polymerase chain reaction study.

Authors:  Glyn Chidlow; Paul S Hiscott; Neville N Osborne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-10       Impact factor: 3.117

3.  Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Francesco Semeraro; Adolfo Sebastiani
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 4.  SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Adolfo Sebastiani
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in oclular normotensive and alpha-chymotrypsin-induced ocular hypertensive rabbits.

Authors:  Gustavo Puras; Juan Santafé; José Segarra; Manuel Garrido; José Melena
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-16       Impact factor: 3.117

Review 6.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

7.  Citalopram associated with acute angle-closure glaucoma: case report.

Authors:  Robert Croos; Srinivasa Thirumalai; Sabit Hassan; Jane Da Roza Davis
Journal:  BMC Ophthalmol       Date:  2005-10-04       Impact factor: 2.209

8.  Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study.

Authors:  Vincent Chin-Hung Chen; Mei-Hing Ng; Wei-Che Chiu; Roger S McIntyre; Yena Lee; Tsang-Yaw Lin; Jun-Cheng Weng; Pau-Chung Chen; Chung-Yao Hsu
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

9.  Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy.

Authors:  Aniruddha Agarwal; Kanika Aggarwal; Aman Kumar; Vishali Gupta
Journal:  Am J Ophthalmol Case Rep       Date:  2018-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.